These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22399516)

  • 61. Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the Prevention of Renal and Vascular End-Stage Disease study.
    Flores-Guerrero JL; Connelly MA; Shalaurova I; Gruppen EG; Kieneker LM; Dullaart RPF; Bakker SJL
    J Clin Lipidol; 2019; 13(1):129-137.e1. PubMed ID: 30591414
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).
    Arsenault BJ; Kohli P; Lambert G; DeMicco DA; Laskey R; Messig MM; Kastelein JJ; Waters DD
    Am J Cardiol; 2016 Aug; 118(4):494-8. PubMed ID: 27328952
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.
    Seyfarth J; Reinehr T; Hoyer A; Reinauer C; Bächle C; Karges B; Mayatepek E; Roden M; Hofer SE; Wiegand S; Woelfle J; Kiess W; Rosenbauer J; Holl RW; Meissner T
    J Inherit Metab Dis; 2018 Jan; 41(1):73-79. PubMed ID: 29027597
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
    Ryu SK; Mallat Z; Benessiano J; Tedgui A; Olsson AG; Bao W; Schwartz GG; Tsimikas S;
    Circulation; 2012 Feb; 125(6):757-66. PubMed ID: 22230483
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of Serum LP-PLA2 Level and some Nutritional Factors between Well-Controlled and Poorly-Controlled Diabetic Patients.
    Cheraghi A; Mahmoudi M; Jafarian K; Eshraghian M; Soltani S; Zarei M; Godarzi F; Kalikias Y; Jalali M
    Acta Med Iran; 2015 Nov; 53(11):690-6. PubMed ID: 26786990
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.
    Hu G; Liu D; Tong H; Huang W; Hu Y; Huang Y
    Biomed Res Int; 2019; 2019():8642784. PubMed ID: 31236414
    [TBL] [Abstract][Full Text] [Related]  

  • 67. n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.
    Steffen BT; Steffen LM; Liang S; Tracy R; Jenny NS; Tsai MY
    Br J Nutr; 2013 Nov; 110(9):1664-71. PubMed ID: 23551952
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association of lipoprotein-associated phospholipase A
    Garg PK; Bartz TM; Norby FL; Jorgensen NW; McClelland RL; Ballantyne CM; Chen LY; Gottdiener JS; Greenland P; Hoogeveen R; Jenny NS; Kizer JR; Rosenson RS; Soliman EZ; Cushman M; Alonso A; Heckbert SR
    Am Heart J; 2018 Mar; 197():62-69. PubMed ID: 29447785
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.
    Garza CA; Montori VM; McConnell JP; Somers VK; Kullo IJ; Lopez-Jimenez F
    Mayo Clin Proc; 2007 Feb; 82(2):159-65. PubMed ID: 17290721
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children.
    Sakka S; Siahanidou T; Voyatzis C; Pervanidou P; Kaminioti C; Lazopoulou N; Kanaka-Gantenbein C; Chrousos GP; Papassotiriou I
    Clin Chem Lab Med; 2015 Jun; 53(7):1119-25. PubMed ID: 25581763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.
    Gong HP; Du YM; Zhong LN; Dong ZQ; Wang X; Mao YJ; Lu QH
    Lipids Health Dis; 2011 Jan; 10():13. PubMed ID: 21247435
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biomarkers for Prediction of Cardiovascular Events in Community-Dwelling Adults Aged 40 or Older.
    Chong Y; Ren Q; Li Y; Li C; Feng F; Zhou Y
    Int Heart J; 2020 Jan; 61(1):109-114. PubMed ID: 31875617
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.
    Ueshima H; Kadowaki T; Hisamatsu T; Fujiyoshi A; Miura K; Ohkubo T; Sekikawa A; Kadota A; Kadowaki S; Nakamura Y; Miyagawa N; Okamura T; Kita Y; Takashima N; Kashiwagi A; Maegawa H; Horie M; Yamamoto T; Kimura T; Kita T;
    Atherosclerosis; 2016 Mar; 246():141-7. PubMed ID: 26775119
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).
    Paik JK; Kim JY; Kim OY; Lee Y; Jeong TS; Sweeney G; Jang Y; Lee JH
    PLoS One; 2012; 7(2):e29675. PubMed ID: 22359537
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
    Hu Y; Li TT; Zhou W; Lu TT; Li FF; Ding B; Liu BL; Xie XJ; Ma JH
    Diabetes Res Clin Pract; 2019 Apr; 150():194-201. PubMed ID: 30904742
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.
    Heart Protection Study Collaborative Group
    J Intern Med; 2010 Oct; 268(4):348-58. PubMed ID: 21050287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.